NCT00864721

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: US Oncology Research · Industry
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Detailed description

In this trial, the activity and tolerability of sunitinib malate (Sutent) will be examined in previously untreated elderly patients (\>70 years old) felt not to be candidates for standard cytotoxic chemotherapy.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sutent	Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.

Timeline

• Start date: 2009-02-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2009-03-19
• Last updated: 2018-10-16
• Results posted: 2018-10-16

Locations

13 sites across 1 country: United States